Estrella Immunopharma, Inc. - *W EXP 09/29/202 (ESLAW)

CUSIP: 297584112

Q3 2026 13F Holders as of 30 Sep 2026

Security type / class
Equity / *W EXP 09/29/202
Total 13F shares
12,000
Total 13F value
$5,600
Share change
0
SEC-reported price per share
$0.47
Number of holders
1

Security key

297584112

Report period

Q3 2026

Institutions

1

Top holders

1

ESLAW full security history Ownership snapshot Full 13F holder table Estrella Immunopharma, Inc. SEC filings Estrella Immunopharma, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of ESLAW - Estrella Immunopharma, Inc. - *W EXP 09/29/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
1/15
Latest evidence
25 Aug 2026
13F 13D/G 3/4/5 Lead comparable stake: 5% 14 rows are not safely comparable across share classes. 13D/G row: ARMISTICE CAPITAL, LLC Showing 1-6 of 15 holder rows.

Quick read

ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership Top 1
ARMISTICE CAPITAL, LLC 5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ARMISTICE CAPITAL, LLC
13F 13D/G
Company
13F 13D/G
5%
Reported 13D/G · 30 Jun 2026
$4,134,229
3,975,220 shares
 — 30 Jun 2026
Eureka Therapeutics, Inc.
3/4/5
10%+ Owner
3/4/5
—
denominator unverified
—
25,277,831 shares
 — 29 Sep 2023
TradeUP Acquisition Sponsor LLC
3/4/5
Former 10% owner
3/4/5
—
denominator unverified
—
1,145,760 shares
 — 29 Sep 2023
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$433,526
416,852 shares
 — 30 Jun 2026
Cheng Liu
3/4/5
CEO, Director
3/4/5
—
mixed-class rows
$413,334
2,297,436 shares
mixed-class rows
 — 25 Aug 2026
Jiandong Xu
3/4/5
Chief Financial Officer
3/4/5
—
mixed-class rows
$399,479
1,282,187 shares
mixed-class rows
 — 18 Aug 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
1
Shares
12,000
Rows available
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
8
Q3 2026 holders
1
Holder diff
-7
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .